Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BioAtla, Inc.BCAB · Entity 879 | Director | June 18, 2025 | June 18, 2025 |
| GYRE THERAPEUTICS, INC.CBIO · Entity 5247 | Director | January 07, 2022 | January 07, 2022 |
| Tessera Defense & Homeland Security Inc.PHGE · Entity 8384 | Director | April 14, 2025 | April 21, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BioAtla, Inc.
Report date June 18, 2025 · Filed June 18, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 60,200 |
Reported balance
After 2025-06-18 transaction · row 1
1 source rowRow 1 · 2025-06-18 · Grant · Acquired 23,500 · Balance 60,200 F1: Represents shares of Common Stock underlying a time-based restricted stock unit award ("RSU"). The RSU will vest as to 100% of the total number of shares on the earlier of (i) June 18, 2026, or (ii) the next Company annual meeting of stockholders, subject to the reporting person's continued service through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of Common Stock underlying a time-based restricted stock unit award ("RSU"). The RSU will vest as to 100% of the total number of shares on the earlier of (i) June 18, 2026, or (ii) the next Company annual meeting of stockholders, subject to the reporting person's continued service through the vesting date.
GYRE THERAPEUTICS, INC.
Report date January 07, 2022 · Filed January 07, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 34,804 |
Reported balance
After 2022-01-07 transaction · row 1
1 source rowRow 1 · 2022-01-07 · Grant · Acquired 12,308 · Balance 34,804 F1: Represents shares of common stock received in lieu of fees. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock received in lieu of fees.
Tessera Defense & Homeland Security Inc.
Report date April 14, 2025 · Filed April 21, 2025 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock Options - right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $0.54 · Expires 2035-04-14 | Direct | 17,600 |
Reported balance
After 2025-04-14 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2025-04-14 · Grant · Acquired 17,600 · Balance 17,600 F1: The options vest and become exercisable over four years, with 25% of the shares of common stock subject to the option vesting on April 14, 2026, and the reminder vesting in 12 equal quarterly installments over three years. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest and become exercisable over four years, with 25% of the shares of common stock subject to the option vesting on April 14, 2026, and the reminder vesting in 12 equal quarterly installments over three years.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 18, 2025 Filed Jun 18, 2025 19:44 UTC | BioAtla, Inc. BCAB · Entity 879 | GrantCommon Stock | 23,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-088064 · ownership.xml · nonDerivative · entry 1 Williams Eddie · CIK 0001725276 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,200 F1 · shares: Represents shares of Common Stock underlying a time-based restricted stock unit award ("RSU"). The RSU will vest as to 100% of the total number of shares on the earlier of (i) June 18, 2026, or (ii) the next Company annual meeting of stockholders, subject to the reporting person's continued service through the vesting date. Read SEC document |
| April 14, 2025 Filed Apr 18, 2025 16:01 UTC | Tessera Defense & Homeland Security Inc. PHGE · Entity 8384 | GrantCommon Stock Options - right to Buy · Derivative | 17,600 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0001213900-25-033354 · ownership.xml · derivative · entry 1 Williams Eddie · CIK 0001725276 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,600 Underlying: Common Stock · 17,600 shares Expires 2035-04-14 F1 · derivative.exercise_date: The options vest and become exercisable over four years, with 25% of the shares of common stock subject to the option vesting on April 14, 2026, and the reminder vesting in 12 equal quarterly installments over three years. Read SEC document |
| April 14, 2025 Filed Apr 21, 2025 08:06 UTC Amendment | Tessera Defense & Homeland Security Inc. PHGE · Entity 8384 | GrantCommon Stock Options - right to Buy · Derivative | 17,600 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0001213900-25-033480 · ownership.xml · derivative · entry 1 Williams Eddie · CIK 0001725276 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,600 Underlying: Common Stock · 17,600 shares Expires 2035-04-14 F1 · derivative.exercise_date: The options vest and become exercisable over four years, with 25% of the shares of common stock subject to the option vesting on April 14, 2026, and the reminder vesting in 12 equal quarterly installments over three years. Read SEC document |
| July 11, 2024 Filed Jul 15, 2024 18:42 UTC | Tessera Defense & Homeland Security Inc. PHGE · Entity 8384 | GrantCommon Stock Options - Right to Buy · Derivative | 176,000 | $0.00 Strike: $0.36 | $0.00 |
DisclosureSEC source: 0001213900-24-061452 · ownership.xml · derivative · entry 1 Williams Eddie · CIK 0001725276 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 176,000 Underlying: Common Stock · 176,000 shares Expires 2034-07-11 F1 · derivative.exercise_date: The options vest and become exercisable over four years, with 25% of the shares subject to the option vesting on July 11, 2025, and the remainder vesting in 12 equal quarterly installments over three years. Read SEC document |
| June 13, 2024 Filed Jun 14, 2024 16:14 UTC | BioAtla, Inc. BCAB · Entity 879 | GrantCommon Stock | 16,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-073662 · ownership.xml · nonDerivative · entry 1 Williams Eddie · CIK 0001725276 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,700 F1 · shares: Represents shares of Common Stock underlying a time-based restricted stock unit award ("RSU"). The RSU will vest as to 100% of the total number of shares on the earlier of (i) June 13, 2025, and (ii) the next Company annual meeting of stockholders, subject to the reporting person's continued service through the vesting date. Read SEC document |
| December 31, 2023 Filed Jan 3, 2024 20:20 UTC | BioAtla, Inc. BCAB · Entity 879 | GrantCommon Stock | 4,827 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-000603 · doc4.xml · nonDerivative · entry 1 Williams Eddie · CIK 0001725276 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,200 F1 · shares: The reporting person has elected to receive fully vested shares of the Issuer's common stock in lieu of cash retainer fees payable for service on the Issuer's Board of Directors and any committees thereof. The number of shares issued represents the quotient of (A) the amount of such fees divided by (B) the Issuer's closing stock price on the date such fees would otherwise be paid, rounded up to the nearest whole share. Read SEC document |
| October 19, 2023 Filed Oct 23, 2023 16:26 UTC | Tessera Defense & Homeland Security Inc. PHGE · Entity 8384 | GrantCommon Stock Options - Right to Buy · Derivative | 41,000 | $0.00 Strike: $0.32 | $0.00 |
DisclosureSEC source: 0001013762-23-005831 · ownership.xml · derivative · entry 1 Williams Eddie · CIK 0001725276 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,000 Underlying: Common Stock · 0 shares Expires 2033-10-19 F1 · derivative.exercise_date: The options vest and become exercisable over four years, with 25% of the shares subject to the option vesting on October 19, 2024, and the remainder vesting in 12 equal quarterly installments over three years. Read SEC document |
| September 30, 2023 Filed Oct 3, 2023 18:23 UTC | BioAtla, Inc. BCAB · Entity 879 | GrantCommon Stock | 6,985 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-051692 · doc4.xml · nonDerivative · entry 1 Williams Eddie · CIK 0001725276 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,373 F1 · shares: The reporting person has elected to receive fully vested shares of the Issuer's common stock in lieu of cash retainer fees payable for service on the Issuer's Board of Directors and any committees thereof. The number of shares issued represents the quotient of (A) the amount of such fees divided by (B) the Issuer's closing stock price on the date such fees would otherwise be paid, rounded up to the nearest whole share. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 17:25 UTC | BioAtla, Inc. BCAB · Entity 879 | GrantCommon Stock | 3,958 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-041217 · doc4.xml · nonDerivative · entry 1 Williams Eddie · CIK 0001725276 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,388 F1 · shares: The reporting person has elected to receive fully vested shares of the Issuer's common stock in lieu of cash retainer fees payable for service on the Issuer's Board of Directors and any committees thereof. The number of shares issued represents the quotient of (A) the amount of such fees divided by (B) the Issuer's closing stock price on the date such fees would otherwise be paid, rounded up to the nearest whole share. Read SEC document |
| June 14, 2023 Filed Jun 15, 2023 18:42 UTC | BioAtla, Inc. BCAB · Entity 879 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $3.55 | $0.00 |
DisclosureSEC source: 0001209191-23-037548 · doc4.xml · derivative · entry 1 Williams Eddie · CIK 0001725276 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2033-06-14 F1 · derivative.exercise_date: 100% of the total number of shares subject to the option shall vest and become exercisable on the earlier of (a) June 14, 2024 or (b) the day before the next annual meeting of stockholders, subject to the reporting person continuing to provide services through the vesting date. Read SEC document |
| March 31, 2023 Filed May 15, 2023 21:12 UTC | BioAtla, Inc. BCAB · Entity 879 | GrantCommon Stock | 4,430 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-029632 · doc4.xml · nonDerivative · entry 1 Williams Eddie · CIK 0001725276 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,430 F1 · shares: The reporting person has elected to receive fully vested shares of the Issuer's common stock in lieu of cash retainer fees payable for service on the Issuer's Board of Directors and any committees thereof. The number of shares issued represents the quotient of (A) the amount of such fees divided by (B) the Issuer's closing stock price on the date such fees would otherwise be paid, rounded up to the nearest whole share. Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 19:54 UTC | BioAtla, Inc. BCAB · Entity 879 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001209191-22-038177 · doc4.xml · derivative · entry 1 Williams Eddie · CIK 0001725276 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-06-16 F1 · derivative.exercise_date: 100% of the total number of shares subject to the option shall vest and become exercisable on the earlier of (a) June 16, 2023 or (b) the next annual meeting of stockholders, subject to the reporting person continuing to provide services through the vesting date. Read SEC document |
| January 07, 2022 Filed Jan 7, 2022 22:33 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantCommon Stock | 12,308 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-002488 · doc4.xml · nonDerivative · entry 1 Williams Eddie · CIK 0001725276 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,804 F1 · shares: Represents shares of common stock received in lieu of fees. Read SEC document |
| December 16, 2021 Filed Feb 2, 2022 17:52 UTC | BioAtla, Inc. BCAB · Entity 879 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $19.57 | $0.00 |
DisclosureSEC source: 0001209191-22-006516 · doc4.xml · derivative · entry 1 Williams Eddie · CIK 0001725276 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-12-16 F1 · derivative.exercise_date: The Option will vest and become exercisable as follows: (i) 8,333 Shares will vest Shares on the first anniversary of the date of grant, (ii) 694 Shares on the last day of the next 23 months commencing with the month next following such first anniversary and (iii) 705 Shares on the last day of the 24th month next following such first anniversary, subject to Mr. Williams continuing to provide services to the Company through the vesting date. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 20:34 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantCommon Stock | 2,980 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-059436 · doc4.xml · nonDerivative · entry 1 Williams Eddie · CIK 0001725276 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,496 F1 · shares: Represents shares of common stock received in lieu of fees. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 13:56 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantCommon Stock | 1,414 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-044693 · doc4.xml · nonDerivative · entry 1 Williams Eddie · CIK 0001725276 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,516 F1 · shares: Represents shares of common stock received in lieu of fees. Read SEC document |
| June 09, 2021 Filed Jul 2, 2021 13:56 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $4.55 | $0.00 |
DisclosureSEC source: 0001209191-21-044693 · doc4.xml · derivative · entry 2 Williams Eddie · CIK 0001725276 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2031-06-09 F2 · derivative.exercise_date: 100% of the shares subject to the option will vest and become exercisable on June 9, 2022, the one-year anniversary of the grant date. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 17:41 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantCommon Stock | 1,215 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-025037 · doc4.xml · nonDerivative · entry 1 Williams Eddie · CIK 0001725276 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,102 F1 · shares: Represents shares of common stock received in lieu of fees. Read SEC document |
| January 05, 2021 Filed Jan 6, 2021 22:01 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantCommon Stock | 940 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-002169 · doc4.xml · nonDerivative · entry 1 Williams Eddie · CIK 0001725276 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,887 F1 · shares: Represents shares of common stock received in lieu of fees. Read SEC document |
| October 01, 2020 Filed Oct 2, 2020 20:23 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantCommon Stock | 1,380 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-053132 · doc4.xml · nonDerivative · entry 1 Williams Eddie · CIK 0001725276 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,947 F1 · shares: Represents shares of common stock received in lieu of fees. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 20:47 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantCommon Stock | 1,011 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-040412 · doc4.xml · nonDerivative · entry 1 Williams Eddie · CIK 0001725276 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,567 F1 · shares: Represents shares of common stock received in lieu of fees. Read SEC document |
| June 11, 2020 Filed Jun 12, 2020 20:49 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $7.18 | $0.00 |
DisclosureSEC source: 0001209191-20-036319 · doc4.xml · derivative · entry 1 Williams Eddie · CIK 0001725276 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2030-06-11 F1 · derivative.exercise_date: The option shall vest monthly over a period of 12 months commencing June 11, 2020. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:44 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantCommon Stock | 2,717 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-023204 · doc4.xml · nonDerivative · entry 1 Williams Eddie · CIK 0001725276 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,556 F1 · shares: Represents shares of common stock received in lieu of fees. Read SEC document |
| March 04, 2020 Filed Mar 4, 2020 21:18 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | PurchaseCommon Stock | 2,000 | $5.78 | $11,560.00 |
DisclosureSEC source: 0001209191-20-016061 · doc4.xml · nonDerivative · entry 1 Williams Eddie · CIK 0001725276 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,839 Read SEC document |
| January 02, 2020 Filed Jan 2, 2020 21:46 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantCommon Stock | 1,743 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-000342 · doc4.xml · nonDerivative · entry 1 Williams Eddie · CIK 0001725276 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,839 F1 · shares: Represents shares of stock received in lieu of fees. Read SEC document |
| October 01, 2019 Filed Oct 2, 2019 20:09 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantCommon Stock | 2,418 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-051626 · doc4.xml · nonDerivative · entry 1 Williams Eddie · CIK 0001725276 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,096 F1 · shares: Represents shares of stock received in lieu of fees. Read SEC document |
| July 01, 2019 Filed Jul 2, 2019 20:51 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantCommon Stock | 1,642 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-040363 · doc4.xml · nonDerivative · entry 1 Williams Eddie · CIK 0001725276 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,678 F1 · shares: Represents shares of stock received in lieu of fees. Read SEC document |
| June 13, 2019 Filed Jun 18, 2019 01:14 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $7.46 | $0.00 |
DisclosureSEC source: 0001209191-19-037571 · doc4.xml · derivative · entry 1 Williams Eddie · CIK 0001725276 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2029-06-13 F1 · derivative.exercise_date: The option shall vest monthly over a period of 12 months commencing June 13, 2019. Read SEC document |
| April 01, 2019 Filed Apr 2, 2019 20:38 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantCommon Stock | 1,364 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-022543 · doc4.xml · nonDerivative · entry 1 Williams Eddie · CIK 0001725276 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,036 F1 · shares: Represents shares of stock received in lieu of fees. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 22:45 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantCommon Stock | 1,544 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-001224 · doc4.xml · nonDerivative · entry 1 Williams Eddie · CIK 0001725276 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,672 F1 · shares: Represents shares of stock received in lieu of fees. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 21:57 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $24.94 | $0.00 |
DisclosureSEC source: 0001209191-18-038139 · doc4.xml · derivative · entry 1 Williams Eddie · CIK 0001725276 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2028-06-13 F1 · derivative.exercise_date: The option shall vest monthly over a period of 12 months commencing June 13, 2018. Read SEC document |
| January 02, 2018 Filed Jan 2, 2018 23:49 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $14.37 | $0.00 |
DisclosureSEC source: 0001209191-18-000364 · doc4.xml · derivative · entry 1 Williams Eddie · CIK 0001725276 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-01-02 F1 · derivative.exercise_date: The Option shall vest monthly over a period of three years commencing January 2, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.